Evidence map›Paper›PMID 28615732›Full record

ReviewNature reviews. Rheumatology2017

Managing rheumatic and musculoskeletal diseases - past, present and future.

Gerd R Burmester, Johannes W J Bijlsma, Maurizio Cutolo, Iain B McInnes

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06460168 (Comparative Effects of Mulligan and Maitland Techniques on Pain, Range of Motion and Functional Disability in Post Prp Knee Osteoarthritis), which is not on this map. Cited by 69 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 3 pooled it
11.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06460168 nacompletednot on this mapstarted 2024, after this paper: background citation

Comparative Effects of Mulligan and Maitland Techniques on Pain, Range of Motion and Functional Disability in Post Prp Knee Osteoarthritis

TypeinterventionalSponsorRiphah International UniversityRan2024 to 2025Enrolled36ConditionsKnee OsteoarthritisArmsMulligan(MWM) MobilizationTechnique, Maitland Mobilization technique
3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 3 syntheses or guidelines pooled it, 160 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Increased Susceptibility toLife (Basel, Switzerland) · 2025
    Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 4 countries.

Gerd R BurmesterDepartment of Rheumatology and Clinical Immunology, Charité - University Medicine, Charitéplatz 1, 10117 Berlin, Germany.
Johannes W J BijlsmaDepartment of Rheumatology and Clinical Immunology, University Medical Center Utrecht, BOX 85 500, 3508CX Utrecht, Netherlands.
Maurizio CutoloResearch Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Viale Benedetto XV, 6, 16132 Genova, Italy.
Iain B McInnesInstitute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, 120 University Place, Glasgow G12 8TA, UK.
Charité - Universitätsmedizin Berlin · DEUniversity Medical Center Utrecht · NLUniversity of Genoa · ITUniversity of Glasgow · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Progress in rheumatology has been remarkable in the past 70 years, favourably affecting quality of life for people with rheumatic and musculoskeletal diseases. Therapeutics have advanced considerably in this period, from early developments such as the introduction of glucocorticoid therapy to the general use of methotrexate and other disease-modifying agents, followed by the advent of biologic DMARDs and, most recently, small-molecule signalling inhibitors. Novel strategies for the use of such agents have also transformed outcomes, as have multidisciplinary nonpharmacological approaches to the management of rheumatic musculoskeletal disease including surgery, physical therapy and occupational therapy. Breakthroughs in our understanding of disease pathogenesis, diagnostics and the use of 'big data' continue to drive the field forward. Critically, the patient is now at the centre of management strategies as well as the future research agenda.

Indexed as

Antirheumatic AgentsBiological ProductsDisease ManagementHumansMusculoskeletal DiseasesOccupational TherapyPhysical Therapy ModalitiesQuality of LifeRheumatic DiseasesAntirheumatic AgentsBiological Products

Identifiers

PMID28615732
OpenAlexW2625784621

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.